---
title: "Pulmonx publishes investor presentation on Zephyr endobronchial valves for severe emphysema treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294259835.md"
description: "Pulmonx published an investor presentation highlighting a USD 12 billion market opportunity for its Zephyr endobronchial valves in severe emphysema treatment. The company reported Q2 2026 revenue of USD 22.8 million with a 78% gross margin and held USD 55.8 million in cash and equivalents. Pulmonx noted over 50,000 patients treated globally and outlined its investigational AeriSeal program, which could expand the addressable market by at least 20%."
datetime: "2026-07-29T20:47:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294259835.md)
  - [en](https://longbridge.com/en/news/294259835.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294259835.md)
---

# Pulmonx publishes investor presentation on Zephyr endobronchial valves for severe emphysema treatment

-   Pulmonx highlighted a USD 12 billion market opportunity for Zephyr endobronchial valves in severe emphysema. \* Reported 2Q26 revenue of USD 22.8 million, including USD 14.2 million in the US, with gross margin of 78%. \* Cash, cash equivalents, and marketable securities totaled USD 55.8 million as of 6/30/2026. \* Noted more than 50,000 patients treated globally, supported by four randomized trials and more than 100 scientific publications. \* Outlined AeriSeal as an investigational program aimed at converting some ineligible patients, with potential to expand addressable market by at least 20%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmonx Corporation published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [LUNG.US](https://longbridge.com/en/quote/LUNG.US.md)

## Related News & Research

- [Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year](https://longbridge.com/en/news/295992856.md)
- [Eupraxia posts corporate presentation detailing RESOLVE trial symptom response data](https://longbridge.com/en/news/295794647.md)
- [Sagimet wins FDA IND clearance for Phase 3 denifanstat acne trial](https://longbridge.com/en/news/295786871.md)
- [Definium Therapeutics publishes corporate presentation outlining DT120 ODT clinical development pipeline in mental health indications](https://longbridge.com/en/news/295840904.md)
- [Sagimet Biosciences Gets FDA Clearance For Phase 3 Acne Study](https://longbridge.com/en/news/295789901.md)